Celgene Limited, the UK subsidiary of Celgene Corporation, has announced that Revlimid is now licensed in the UK for newly diagnosed myeloma patients who are not eligible for high-dose therapy and stem cell transplantation. Licensing approval of Revlimid in this setting was based on data from the FIRST trial, MM-020, which showed that progression-free survival and overall survival were significantly improved in patients receiving continuous Revlimid and low-dose dexamethasone (Rd) compared to those receiving the standard treatment of melphalan, thalidomide and prednisolone (MPT). The National Institute for Health and Care Excellence (NICE) is conducting a single technology appraisal for Revlimid as front-line treatment for myeloma patients. A decision is expected next year.

Read full article